Karim Vermaelen
- Immunology top 2%
- Pulmonary and Respiratory Medicine top 2%
- Physiology top 5%
- Molecular Biology
- Oncology top 5%
- Co-authors
- Romain PauwelsGuy BrusselleBart N. LambrechtIngel DemedtsJan P. van MeerbeeckGuy JoosA. I. D'hulstRuben Pauwels
- Topics
- Immunotherapy and Immune Responses (15 papers)Cancer Immunotherapy and Biomarkers (11 papers)Lung Cancer Treatments and Mutations (8 papers)
- Journals
- Proceedings of the National Academy of SciencesThe Journal of Experimental MedicineJournal of Clinical Oncology
- Partner nations
- BelgiumNetherlandsUnited States
In The Last Decade
Karim Vermaelen
56 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 126
- Immunology 1.5k
- Pulmonary and Respiratory Medicine 869
- Physiology 713
- Molecular Biology 670
- Oncology 546
Countries citing papers authored by Karim Vermaelen
This map shows the geographic impact of Karim Vermaelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim Vermaelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim Vermaelen more than expected).
Fields of papers citing papers by Karim Vermaelen
This network shows the impact of papers produced by Karim Vermaelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim Vermaelen. The network helps show where Karim Vermaelen may publish in the future.
Co-authorship network of co-authors of Karim Vermaelen
This figure shows the co-authorship network connecting the top 25 collaborators of Karim Vermaelen. A scholar is included among the top collaborators of Karim Vermaelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karim Vermaelen. Karim Vermaelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 0 | |
| 3 | 18 | |
| 4 | 9 | |
| 5 | 26 | |
| 6 | The ION-Ghent guidelines for the management of immune related adverse events (irAE's) | 1 |
| 7 | 29 | |
| 8 | Second opinion for thoracic cancer and its impact on diagnosis and treatment strategy: a single institutional series | 2 |
| 9 | Resistance training in patients with radically treated respiratory cancer: mature results of a multi-centre randomised phase 3 trial (REINFORCE) | 3 |
| 10 | 42 | |
| 11 | Effect of radical treatment on exercise capacity and muscle force in patients with intrathoracic cancer | 0 |
| 12 | 68 | |
| 13 | Trimodality treatment of early stage Malignant Pleural Mesothelioma (MPM): a single institutional experience | 1 |
| 14 | 30 | |
| 15 | 20 | |
| 16 | 4 | |
| 17 | 78 | |
| 18 | 211 | |
| 19 | 124 | |
| 20 | 147 |
About Karim Vermaelen
Karim Vermaelen is a scholar working on Microbiology, Immunology and Oncology, having authored 60 papers that have together received 3.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Immunology (1.5k citations), Immunology and Allergy (214 citations) and Physiology (713 citations). Karim Vermaelen has collaborated with scholars based in Belgium, Netherlands and United States. Frequent co-authors include Romain Pauwels, Guy Brusselle, Bart N. Lambrecht, Ingel Demedts, Jan P. van Meerbeeck, Guy Joos, A. I. D'hulst, Ruben Pauwels, Ken R. Bracke and Mélissa Dullaers. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.